InvestorsHub Logo
Followers 8
Posts 443
Boards Moderated 0
Alias Born 03/25/2016

Re: chumppunk post# 14106

Wednesday, 04/26/2017 1:07:44 PM

Wednesday, April 26, 2017 1:07:44 PM

Post# of 232880
IMO, as long as Clinical Trial results remain good, worst case scenario is a BO at $2.50 - $4.00 per share. Of course, this is not full value, but without an extraordinary capital infusion to complete the trials, CYDY's value will be a heavily discounted by an acquiring company. Just the price of not raising sufficient capital on the front end, which is not a criticism of management, as alternatives were most likely limited early on.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News